Inclusion Criteria:
1. Subject is ≥18 years old.
2. Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the femoral artery using 8-22 French introducer sheaths such as TAVI/TAVR/EVAR/TEVAR etc.
3. Subject has suitable sized vessel / calcification as evaluated on pre-procedural CT angiography by the investigator and by the study' screening committee
4. Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery
5. Understand and sign the study specific written informed consent form
6. Able and willing to fulfill the follow-up requirements
Exclusion Criteria:
Baseline Exclusions:
1. Known to be pregnant or lactating.
2. Immunocompromised or with pre-existing autoimmune disease.
3. Systemic infection or a local infection at or near the access site.
4. Significant anemia (Hgb \< 9 g/dL hematocrit \<30%).
5. Morbidly obese or cachectic (BMI \>40 kg/m2 or \<20kg/m2).
6. Known bleeding disorders including thrombocytopenia (platelet count \<100,000 cells/UL), thrombasthenia, hemophilia, von Willebrand disease, or hypercoagulability.
7. Known allergy to any device component.
8. Femoral artery puncture in target groin within the prior 14 days, recent femoral artery puncture in target groin that has not healed appropriately, and/or prior vascular closure device placement in target common femoral artery that the investigator determines may interfere with the NVCS.
9. Common femoral artery with calcium, as determined by baseline CTA, precluding safe access in the opinion of the investigator or severe peripheral vascular disease as evidenced by severe claudication when ambulating \< 30 meter, weak or absent pulses in the affected limb.
10. Previous intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area.
11. Prior target artery closure with any closure device \< 180 days, or closure with manual compression ≤ 90 days prior to index procedure.
12. Subjects who have undergone use of an intra-aortic balloon pump through the arterial access site.
13. Undergoing therapeutic thrombolysis.
14. Subjects in whom oral anticoagulation therapy cannot be stopped for the peri-procedural period or subjects with INR \>1.8 at the time of the procedure.
15. Subject unable to be adequately anti-coagulated for the procedure.
16. Subjects who are not mobile and are confined to a wheelchair or bed.
17. ST-elevation MI within 45 days prior to procedure or acute coronary syndrome (i.e., unstable angina or myocardial infarction) ≤14 days before the catheterization procedure
18. NYHA class IV heart failure.
19. Left ventricular ejection fraction \<20%.
20. Unilateral or bilateral lower extremity amputation.
21. Renal insufficiency (serum creatinine \>2.5 mg/dl) or on dialysis therapy, or after renal transplant.
22. Existing nerve damage in the NVCS treated leg.
23. Further planned endovascular procedure within the next 30 days.
24. Subjects currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period.
25. Subject cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life-threatening disease.
26. Common femoral artery \<6mm or \>50% diameter femoral stenosis by baseline CTA and/or severe peripheral arterial disease or Rutherford Classification 5 or 6.
27. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
28. Known severe allergy to contrast reagent that cannot be managed with premedication.
29. Connective tissue disease (e.g., Marfan's Syndrome).
30. Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure.
31. Subject is mentally incompetent or a prisoner.
32. Planned antegrade puncture during the index procedure.
33. Stenosis \>50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.
34. Subject unable to ambulate at baseline (i.e., confined to wheelchair or bed).
Intra-Procedure Exclusions:
1. On baseline Duplex US the Common femoral artery \<6mm or \>50% stenosis of the femoral artery.
2. Puncture site took place in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries or if less than one third of the access needle is above the skin line indicating the subject is morbidly obese.
3. Common femoral artery suspected to have experienced a back wall puncture or underwent \> one (1) arterial puncture during the catheterization procedure.
4. Difficult dilation from initial femoral artery access (e.g., damaging or kinking dilators) while step dilating up to the large-bore device.
5. Actual puncture site located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks.
6. Marked tortuosity of femoral or iliac artery that to the opinion of the user prohibiting the use of the device.
7. Systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mm Hg, unless systolic or diastolic pressure can be lowered by pharmacological agents prior to closure.
8. Planned antegrade puncture during the index procedure.
9. Possible bacterial contamination of the procedure's sheath or surrounding tissues during the procedure.
10. Intra-procedural complication(s) at the femoral access site before procedural sheath removal and before sliding the NVCS knot down, including: 1. Bleeding or swelling around the sheath that may indicate hematoma formation and/or pseudoaneurysm formation; and 2. Peri-procedural duplex us/angiographic evidence of thrombus formation or significant injury in the aorta or iliac vessels associated with procedural large bore sheath placement and/or sub-optimal anticoagulation.
11. Presence of ipsilateral femoral venous sheath during the interventional procedure.
12. Systolic blood pressure \<90 mm Hg just prior to planned vascular closure without the ability to increase it.
13. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
14. Index procedure planned sheath or interventional device \>22Fr during the procedure.
15. Evidence of a pre-existing hematoma (\> 1.5 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site before insertion of the NVCS.
16. Duplex US (or by angiography if applicable) evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the device.
17. Stenosis \>50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.
